KORU Medical Systems, Inc. (NASDAQ:KRMD) Given Average Rating of “Moderate Buy” by Brokerages

Shares of KORU Medical Systems, Inc. (NASDAQ:KRMD) have received an average recommendation of “Moderate Buy” from the five research firms that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $7.25.

A number of analysts have issued reports on KRMD shares. Canaccord Genuity Group reissued a “buy” rating and issued a $6.00 price objective on shares of KORU Medical Systems in a report on Friday, March 13th. Wall Street Zen downgraded shares of KORU Medical Systems from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. B. Riley Financial boosted their price objective on shares of KORU Medical Systems from $7.00 to $8.00 and gave the company a “buy” rating in a report on Friday, March 13th. Finally, Weiss Ratings downgraded shares of KORU Medical Systems from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 29th.

Institutional Trading of KORU Medical Systems

A number of institutional investors have recently bought and sold shares of the business. Cubist Systematic Strategies LLC lifted its holdings in shares of KORU Medical Systems by 927.4% during the 1st quarter. Cubist Systematic Strategies LLC now owns 77,280 shares of the company’s stock worth $196,000 after acquiring an additional 69,758 shares during the period. Goldman Sachs Group Inc. lifted its holdings in shares of KORU Medical Systems by 189.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 242,781 shares of the company’s stock worth $617,000 after acquiring an additional 158,914 shares during the period. Jane Street Group LLC lifted its holdings in shares of KORU Medical Systems by 136.7% during the 1st quarter. Jane Street Group LLC now owns 163,137 shares of the company’s stock worth $414,000 after acquiring an additional 94,214 shares during the period. Acadian Asset Management LLC bought a new stake in shares of KORU Medical Systems during the 1st quarter worth approximately $63,000. Finally, Geode Capital Management LLC lifted its holdings in shares of KORU Medical Systems by 101.3% during the 2nd quarter. Geode Capital Management LLC now owns 997,147 shares of the company’s stock worth $3,571,000 after acquiring an additional 501,875 shares during the period. Institutional investors own 58.60% of the company’s stock.

KORU Medical Systems Stock Performance

Shares of KRMD stock opened at $4.00 on Wednesday. The company has a market capitalization of $183.72 million, a price-to-earnings ratio of -80.00 and a beta of 0.43. The company has a 50-day simple moving average of $4.12 and a 200 day simple moving average of $4.84. KORU Medical Systems has a 52 week low of $2.91 and a 52 week high of $6.61.

KORU Medical Systems (NASDAQ:KRMD) last announced its earnings results on Thursday, March 12th. The company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.02) by $0.01. The business had revenue of $10.90 million during the quarter, compared to the consensus estimate of $10.90 million. KORU Medical Systems had a negative net margin of 5.27% and a negative return on equity of 13.61%. Sell-side analysts forecast that KORU Medical Systems will post -0.04 EPS for the current year.

About KORU Medical Systems

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.